ECSP23048136A - Compuestos de indazol como inhibidores de cinasas - Google Patents
Compuestos de indazol como inhibidores de cinasasInfo
- Publication number
- ECSP23048136A ECSP23048136A ECSENADI202348136A ECDI202348136A ECSP23048136A EC SP23048136 A ECSP23048136 A EC SP23048136A EC SENADI202348136 A ECSENADI202348136 A EC SENADI202348136A EC DI202348136 A ECDI202348136 A EC DI202348136A EC SP23048136 A ECSP23048136 A EC SP23048136A
- Authority
- EC
- Ecuador
- Prior art keywords
- kinase inhibitors
- indazole compounds
- compounds
- indazole
- disclosed
- Prior art date
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 108091008794 FGF receptors Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063132031P | 2020-12-30 | 2020-12-30 | |
| US202163216879P | 2021-06-30 | 2021-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23048136A true ECSP23048136A (es) | 2023-09-29 |
Family
ID=80168316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202348136A ECSP23048136A (es) | 2020-12-30 | 2023-06-26 | Compuestos de indazol como inhibidores de cinasas |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US12264149B2 (https=) |
| EP (1) | EP4271673A1 (https=) |
| JP (2) | JP7791196B2 (https=) |
| KR (1) | KR20230152654A (https=) |
| AU (1) | AU2021411587B2 (https=) |
| CA (1) | CA3205986A1 (https=) |
| CL (1) | CL2023001951A1 (https=) |
| CO (1) | CO2023008689A2 (https=) |
| CR (1) | CR20230325A (https=) |
| EC (1) | ECSP23048136A (https=) |
| IL (1) | IL304014A (https=) |
| MX (1) | MX2023007793A (https=) |
| PE (1) | PE20240687A1 (https=) |
| WO (1) | WO2022147246A1 (https=) |
| ZA (1) | ZA202306559B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| CR20230325A (es) | 2020-12-30 | 2023-12-11 | Tyra Biosciences Inc | Compuestos de indazol como inhibidores de cinasas |
| JP2025525433A (ja) * | 2022-06-29 | 2025-08-05 | タイラ・バイオサイエンシーズ・インコーポレイテッド | インダゾール化合物 |
| EP4547670A1 (en) * | 2022-06-29 | 2025-05-07 | Tyra Biosciences, Inc. | Polymorphic compounds and uses thereof |
| JP2025529161A (ja) | 2022-08-30 | 2025-09-04 | タイラ・バイオサイエンシーズ・インコーポレイテッド | 活性化ｆｇｆｒ３遺伝子変化を有する固形腫瘍を処置する方法 |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| WO2024137742A1 (en) | 2022-12-20 | 2024-06-27 | Blueprint Medicines Corporation | Compounds and compositions as fgfr3 degraders and uses thereof |
| WO2024138112A1 (en) * | 2022-12-22 | 2024-06-27 | Tyra Biosciences, Inc. | Indazole compounds |
| KR20250128350A (ko) * | 2022-12-30 | 2025-08-27 | 장슈 야홍 메디텍 코퍼레이션 리미티드 | 피라졸 융합된 고리 화합물, 및 이의 제조 방법 및 용도 |
| AU2024240722A1 (en) | 2023-03-20 | 2025-09-18 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
| CN119306723B (zh) * | 2023-07-13 | 2026-04-10 | 长春金赛药业有限责任公司 | 吲唑类fgfr2/3选择性抑制剂、药物组合物及其应用 |
| WO2025021033A1 (zh) * | 2023-07-21 | 2025-01-30 | 长春金赛药业有限责任公司 | 成纤维细胞生长因子受体抑制剂、药物组合物及其应用 |
| WO2025021997A1 (en) | 2023-07-27 | 2025-01-30 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | New map4k1 inhibitors |
| WO2025061029A1 (en) * | 2023-09-18 | 2025-03-27 | 3H Pharmaceuticals Co., Ltd. | Fgfr inhibitors and methods of use thereof |
| TW202519212A (zh) | 2023-09-22 | 2025-05-16 | 美商泰拉生物科學公司 | 組合治療療法 |
| WO2025129014A1 (en) * | 2023-12-15 | 2025-06-19 | Tyra Biosciences, Inc. | Indazole compounds for the treatment of cancer |
| WO2025170959A1 (en) | 2024-02-05 | 2025-08-14 | Tyra Biosciences, Inc. | Combination of the fgfr 3 inhibitor tyra-300 and a nectin-4 targeting agent-drug conjugate for use in the treatment of cancer |
| WO2025199217A1 (en) | 2024-03-19 | 2025-09-25 | Tyra Biosciences, Inc. | Pharmaceutical compositions |
| WO2026020109A1 (en) * | 2024-07-19 | 2026-01-22 | Tyra Biosciences, Inc. | Combination treatment comprising a fgfr3 inhibitor and a pd-1/pd-l1 inhibitor for use in the treatment of cancer |
| WO2026035809A1 (en) * | 2024-08-06 | 2026-02-12 | Tyra Biosciences, Inc. | Indazole compounds for the treatment of cancer |
Family Cites Families (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| JPS62135835A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62135834A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62135832A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62135830A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料及びその処理方法 |
| JPS62136651A (ja) | 1985-12-10 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料の処理方法 |
| JPS62136654A (ja) | 1985-12-10 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の処理方法 |
| JPS62136650A (ja) | 1985-12-11 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料及びその処理方法 |
| US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
| US4748982A (en) | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| GB8808433D0 (en) | 1988-04-11 | 1988-05-11 | Merck Sharp & Dohme | Therapeutic agents |
| CA1322628C (en) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
| US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
| US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
| US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
| US5041453A (en) | 1990-05-30 | 1991-08-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Quinolinyl-benzoheterobicyclic derivatives as antagonists of leukotriene D4 |
| JP2000507955A (ja) | 1996-04-03 | 2000-06-27 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質転移酵素の阻害剤 |
| US6063930A (en) | 1996-04-03 | 2000-05-16 | Merck & Co., Inc. | Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
| HUP0004150A3 (en) | 1997-11-04 | 2001-08-28 | Pfizer Prod Inc | Indazole derivatives as tyrosine kinase receptor antagonists and pharmaceutical compositions containing them |
| WO1999023076A1 (en) | 1997-11-04 | 1999-05-14 | Pfizer Products Inc. | Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors |
| EP1046631A1 (en) | 1999-04-19 | 2000-10-25 | Rolic AG | Liquid crystalline compounds |
| GB9908934D0 (en) | 1999-04-19 | 1999-06-16 | Rolic Ag | Liquid crystalline compounds |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| CN1300116C (zh) | 2001-04-16 | 2007-02-14 | 卫材株式会社 | 1h－吲唑化合物 |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| CA2482838A1 (en) | 2002-05-31 | 2003-12-11 | Eisai Co., Ltd. | Pyrazole compounds and pharmaceutical compositions containing the compound |
| EP1545515A1 (en) | 2002-08-12 | 2005-06-29 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
| JP4847868B2 (ja) | 2003-05-14 | 2011-12-28 | ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド | 化合物、及び、アミロイドベータの調節におけるその使用 |
| EP1723126A2 (en) | 2003-10-22 | 2006-11-22 | Eli Lilly And Company | Novel mch receptor antagonists |
| WO2005060958A1 (en) | 2003-12-19 | 2005-07-07 | Kalypsys, Inc. | (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes |
| US7880002B2 (en) | 2004-12-29 | 2011-02-01 | Millennium Pharmaceuticals, Inc. | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
| US7635698B2 (en) | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| CN101128441A (zh) | 2005-03-04 | 2008-02-20 | 默克公司 | 具有抗糖尿病活性的稠合芳香化合物 |
| WO2007050124A1 (en) | 2005-05-19 | 2007-05-03 | Xenon Pharmaceuticals Inc. | Fused piperidine derivatives and their uses as therapeutic agents |
| WO2007044085A2 (en) | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
| WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| JP5255559B2 (ja) | 2006-03-31 | 2013-08-07 | アボット・ラボラトリーズ | インダゾール化合物 |
| DE102006030479A1 (de) | 2006-07-01 | 2008-03-20 | Merck Patent Gmbh | Indazolderivate |
| WO2008008650A1 (en) | 2006-07-10 | 2008-01-17 | Indiana University Research And Technology Corporation | Methods for treating cystic kidney diseases |
| US20110008347A1 (en) | 2006-12-01 | 2011-01-13 | Agency For Science ,Technology And Research | Cancer-related protein kinases |
| CN101687789A (zh) | 2007-02-12 | 2010-03-31 | 因特蒙公司 | C型肝炎病毒复制的新颖抑制剂 |
| EP2074114B1 (en) | 2007-04-25 | 2013-03-06 | Exelixis, Inc. | Pyrimidinones as casein kinase ii (ck2) modulators |
| US8338458B2 (en) | 2007-05-07 | 2012-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fused aromatic compounds having anti-diabetic activity |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| WO2010065668A1 (en) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| US8759337B2 (en) | 2008-12-22 | 2014-06-24 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| WO2010075273A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
| WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| TW201038569A (en) | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
| WO2010096777A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| US8455516B2 (en) | 2010-01-15 | 2013-06-04 | Touro University | HIV-1 fusion inhibitors and methods |
| KR101483215B1 (ko) | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
| EP2368876A1 (en) | 2010-03-01 | 2011-09-28 | Sanofi | Derivatives of aminoindanes, their preparation and their application in therapeutics |
| WO2011109551A2 (en) | 2010-03-03 | 2011-09-09 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| JP5763937B2 (ja) | 2010-03-10 | 2015-08-12 | Ａｇｃセイミケミカル株式会社 | 液晶化合物、その製造方法、液晶組成物および液晶電気光学素子 |
| MA34300B1 (fr) | 2010-05-13 | 2013-06-01 | Amgen Inc | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 |
| BR112013002112B1 (pt) | 2010-07-29 | 2021-04-06 | Rigel Pharmaceuticals, Inc. | Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição |
| JO3062B1 (ar) * | 2010-10-05 | 2017-03-15 | Lilly Co Eli | R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري |
| US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| US8883793B2 (en) | 2010-12-29 | 2014-11-11 | Development Center For Biotechnology | Tubulin inhibitors and methods of using the same |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| CN103702961A (zh) | 2011-05-23 | 2014-04-02 | 赛诺菲 | 含有n-烷基的氘代化合物的制备方法 |
| CN102243505B (zh) | 2011-07-07 | 2013-08-14 | 矽力杰半导体技术(杭州)有限公司 | 一种低失调、快速响应的电压控制电流源、控制方法以及应用其的电源电路 |
| EP2740803A4 (en) | 2011-08-05 | 2015-03-25 | Astellas Pharma Inc | METHOD FOR RECOGNIZING NEW FGFR4 MUTANTS |
| HK1199259A1 (en) | 2011-08-15 | 2015-06-26 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| BR112014004569A2 (pt) | 2011-09-01 | 2017-06-13 | F. Hoffmann-La Roche Ag | composto da fórmula i, métodos para tratar condição inflamatória, artrite reumatoide, asma e distúrbio imune, composição farmacêutica e uso do composto |
| EP2753605B1 (en) | 2011-09-09 | 2019-03-27 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| US9254288B2 (en) | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
| CN103420906B (zh) | 2012-05-21 | 2015-09-09 | 南京圣和药业股份有限公司 | 新型酪氨酸蛋白激酶抑制剂 |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| CA2890346A1 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| WO2014113485A1 (en) | 2013-01-15 | 2014-07-24 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| EP2945652B1 (en) | 2013-01-18 | 2021-07-07 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| KR101648141B1 (ko) | 2013-06-11 | 2016-08-12 | 제일모직 주식회사 | 화합물, 이를 포함하는 유기 광전자 소자 및 상기 유기 광전자 소자를 포함하는 표시장치 |
| WO2015008844A1 (ja) | 2013-07-18 | 2015-01-22 | 大鵬薬品工業株式会社 | Ｆｇｆｒ阻害剤耐性癌の治療薬 |
| US10323285B2 (en) | 2013-09-09 | 2019-06-18 | Nantomics, Llc | Proteomics analysis and discovery through DNA and RNA sequencing, systems and methods |
| WO2015048547A2 (en) | 2013-09-26 | 2015-04-02 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| US9546162B2 (en) | 2013-09-27 | 2017-01-17 | Allergan, Inc. | Compounds and methods for skin repair |
| WO2015082499A2 (en) | 2013-12-03 | 2015-06-11 | Iomet Pharma Ltd | Pharmaceutical compound |
| CN104946737B (zh) | 2013-12-11 | 2019-02-22 | 安可济控股有限公司 | 用于检测罕见序列变体的组合物和方法 |
| US10391081B2 (en) | 2013-12-27 | 2019-08-27 | Chugai Seiyaku Kabushiki Kaisha | FGFR gatekeeper mutant gene and drug targeting same |
| WO2015103527A1 (en) | 2014-01-06 | 2015-07-09 | The Scripps Research Institute | Modulators of rev-erb |
| US20160340742A1 (en) | 2014-02-04 | 2016-11-24 | Mayo Foundation For Medical Education And Research | Method of Identifying Tyrosine Kinase Receptor Rearrangements in Patients |
| SG11201607772WA (en) | 2014-03-31 | 2016-10-28 | Debiopharm Int Sa | Fgfr fusions |
| US10351527B2 (en) | 2014-04-09 | 2019-07-16 | The University Of British Columbia | Binding function 3 (BF3) site compounds as therapeutics and methods for their use |
| JP6788577B2 (ja) | 2014-05-09 | 2020-11-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 液晶媒体およびそれを含む高周波数素子 |
| ES2842592T3 (es) | 2014-05-19 | 2021-07-14 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos antihelmínticos |
| WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
| CN107427524A (zh) | 2014-08-28 | 2017-12-01 | 翁科埃斯克斯有限公司 | 利用包含噻吩并三唑并二氮杂*化合物的药物组合物治疗急性髓细胞白血病或急性淋巴性白血病的方法 |
| US20170369780A1 (en) | 2014-11-11 | 2017-12-28 | Merck Patent Gmbh | Bimesogenic compounds and mesogenic media |
| JP2018027019A (ja) | 2014-11-26 | 2018-02-22 | 国立研究開発法人国立がん研究センター | 胆道がんにおける新規治療標的融合遺伝子 |
| WO2016105503A1 (en) | 2014-12-24 | 2016-06-30 | Genentech, Inc. | Therapeutic, diagnostic and prognostic methods for cancer of the bladder |
| EP3265462A1 (en) | 2015-03-03 | 2018-01-10 | INSERM - Institut National de la Santé et de la Recherche Médicale | Fgfr3 antagonists |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| WO2016172631A2 (en) | 2015-04-24 | 2016-10-27 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof |
| CN106317023A (zh) * | 2015-07-10 | 2017-01-11 | 中国科学院上海药物研究所 | 吲唑类化合物的制备方法和用途 |
| EP3333157B1 (en) * | 2015-08-07 | 2020-12-23 | Harbin Zhenbao Pharmaceutical Co., Ltd. | Vinyl compounds as fgfr and vegfr inhibitors |
| WO2017066705A1 (en) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| AU2016341259B2 (en) | 2015-10-22 | 2019-09-12 | Selvita S.A. | Pyridone derivatives and their use as kinase inhibitors |
| KR20180118739A (ko) | 2016-03-02 | 2018-10-31 | 제이엔씨 주식회사 | 적층체, 전자 기기, 적층체 제조 방법 |
| US20190055444A1 (en) | 2016-03-02 | 2019-02-21 | Jnc Corporation | Composition for low thermal expansion members, low thermal expansion member, electronic device, and method for producing low thermal expansion member |
| CN109152784B (zh) | 2016-03-16 | 2021-12-28 | 库拉肿瘤学公司 | 经取代的menin-mll抑制剂及使用方法 |
| WO2017194665A1 (en) | 2016-05-12 | 2017-11-16 | Merck Patent Gmbh | Bimesogenic compounds and mesogenic media |
| KR102605996B1 (ko) | 2016-08-30 | 2023-11-27 | 다우 글로벌 테크놀로지스 엘엘씨 | 아크롤레인의 농도의 저감 방법 |
| JP6589795B2 (ja) | 2016-09-27 | 2019-10-16 | 信越化学工業株式会社 | スルホニウム塩、レジスト組成物及びパターン形成方法 |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| WO2019018795A1 (en) | 2017-07-20 | 2019-01-24 | Yumanity Therapeutics | COMPOUNDS AND USES THEREOF |
| WO2019034172A1 (zh) | 2017-08-18 | 2019-02-21 | 上海轶诺药业有限公司 | 一种具有pd-l1抑制活性的化合物、其制备方法及用途 |
| US11795162B2 (en) | 2017-08-18 | 2023-10-24 | Saint Louis University | Modulators of the estrogen-related receptor |
| WO2019209948A1 (en) | 2018-04-25 | 2019-10-31 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| EP3847159A2 (en) | 2018-09-04 | 2021-07-14 | Magenta Therapeutics, Inc. | Aryl hydrocarbon receptor antagonists and methods of use |
| KR102127006B1 (ko) | 2018-12-06 | 2020-06-25 | 한국생산기술연구원 | 피리미딘계 작용기 함유 단분자 화합물, 상기 화합물의 광가교물을 포함한 유기물층 및 이를 포함하는 유기전자소자 |
| CA3124970A1 (en) | 2018-12-28 | 2020-07-02 | Cedars-Sinai Medical Center | Methods of treating inflammatory bowel diseases that target ripk2 |
| CN111434655A (zh) | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 溶血磷脂酸受体拮抗剂及其制备方法 |
| IN201941011265A (https=) * | 2019-03-22 | 2020-09-25 | ||
| TW202108582A (zh) | 2019-05-14 | 2021-03-01 | 大陸商上海翰森生物醫藥科技有限公司 | 含二並環類衍生物抑制劑、其製備方法和應用 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN112409331B (zh) | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| WO2021067374A1 (en) * | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| CN112812014B (zh) | 2019-11-15 | 2024-05-10 | 石家庄诚志永华显示材料有限公司 | 化合物、液晶组合物、液晶显示器 |
| WO2021104305A1 (zh) | 2019-11-26 | 2021-06-03 | 上海翰森生物医药科技有限公司 | 含氮多环类衍生物抑制剂、其制备方法和应用 |
| WO2021127333A1 (en) | 2019-12-19 | 2021-06-24 | Casma Therapeutics, Inc. | Trpml modulators |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| US20230128972A1 (en) | 2020-01-31 | 2023-04-27 | Atomwise Inc. | Anat Inhibitors and Methods of Use Thereof |
| WO2021161230A1 (en) | 2020-02-12 | 2021-08-19 | Curadev Pharma Pvt. Ltd. | Small molecule sting antagonists |
| US20230148214A1 (en) | 2020-03-06 | 2023-05-11 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
| WO2021183970A1 (en) | 2020-03-13 | 2021-09-16 | University Of Maryland, Baltimore | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
| CA3182162A1 (en) | 2020-05-06 | 2021-11-11 | Les Laboratoires Servier | New macrocyclic lrrk2 kinase inhibitors |
| CR20230325A (es) | 2020-12-30 | 2023-12-11 | Tyra Biosciences Inc | Compuestos de indazol como inhibidores de cinasas |
| TW202304935A (zh) | 2021-03-18 | 2023-02-01 | 法商施維雅藥廠 | 新穎的巨環lrrk2激酶抑制劑 |
| WO2022198112A1 (en) | 2021-03-19 | 2022-09-22 | Arvinas Operations, Inc. | Indazole based compounds and associated methods of use |
| US20240316022A1 (en) | 2021-06-30 | 2024-09-26 | Tyra Biosciences, Inc. | Indazole compounds |
| CN119183452A (zh) | 2022-04-04 | 2024-12-24 | 布雷宁疗法公司 | Lrrk2抑制剂 |
| EP4547670A1 (en) | 2022-06-29 | 2025-05-07 | Tyra Biosciences, Inc. | Polymorphic compounds and uses thereof |
| JP2025525433A (ja) | 2022-06-29 | 2025-08-05 | タイラ・バイオサイエンシーズ・インコーポレイテッド | インダゾール化合物 |
| JP2025529161A (ja) | 2022-08-30 | 2025-09-04 | タイラ・バイオサイエンシーズ・インコーポレイテッド | 活性化ｆｇｆｒ３遺伝子変化を有する固形腫瘍を処置する方法 |
-
2021
- 2021-12-30 CR CR20230325A patent/CR20230325A/es unknown
- 2021-12-30 MX MX2023007793A patent/MX2023007793A/es unknown
- 2021-12-30 PE PE2023001961A patent/PE20240687A1/es unknown
- 2021-12-30 CA CA3205986A patent/CA3205986A1/en active Pending
- 2021-12-30 AU AU2021411587A patent/AU2021411587B2/en active Active
- 2021-12-30 WO PCT/US2021/065679 patent/WO2022147246A1/en not_active Ceased
- 2021-12-30 EP EP21852113.6A patent/EP4271673A1/en active Pending
- 2021-12-30 IL IL304014A patent/IL304014A/en unknown
- 2021-12-30 US US18/259,422 patent/US12264149B2/en active Active
- 2021-12-30 KR KR1020237024903A patent/KR20230152654A/ko active Pending
- 2021-12-30 JP JP2023540770A patent/JP7791196B2/ja active Active
-
2023
- 2023-06-26 ZA ZA2023/06559A patent/ZA202306559B/en unknown
- 2023-06-26 EC ECSENADI202348136A patent/ECSP23048136A/es unknown
- 2023-06-30 CO CONC2023/0008689A patent/CO2023008689A2/es unknown
- 2023-06-30 CL CL2023001951A patent/CL2023001951A1/es unknown
-
2024
- 2024-02-22 US US18/584,440 patent/US12071428B2/en active Active
-
2025
- 2025-02-03 US US19/043,650 patent/US20250340533A1/en active Pending
- 2025-12-09 JP JP2025243767A patent/JP2026048777A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2026048777A (ja) | 2026-03-17 |
| KR20230152654A (ko) | 2023-11-03 |
| MX2023007793A (es) | 2023-09-22 |
| JP2024502433A (ja) | 2024-01-19 |
| CO2023008689A2 (es) | 2023-09-29 |
| US20240109865A1 (en) | 2024-04-04 |
| CL2023001951A1 (es) | 2023-12-01 |
| US12264149B2 (en) | 2025-04-01 |
| PE20240687A1 (es) | 2024-04-10 |
| TW202241906A (zh) | 2022-11-01 |
| US12071428B2 (en) | 2024-08-27 |
| US20250340533A1 (en) | 2025-11-06 |
| AU2021411587A1 (en) | 2023-07-06 |
| EP4271673A1 (en) | 2023-11-08 |
| AU2021411587B2 (en) | 2024-10-10 |
| ZA202306559B (en) | 2025-09-25 |
| JP7791196B2 (ja) | 2025-12-23 |
| CA3205986A1 (en) | 2022-07-07 |
| US20240208941A1 (en) | 2024-06-27 |
| CR20230325A (es) | 2023-12-11 |
| WO2022147246A1 (en) | 2022-07-07 |
| IL304014A (en) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001951A1 (es) | Compuestos de indazol como inhibidores de cinasas | |
| ECSP20069404A (es) | Piridazinonas como inhibidoras de parp7 | |
| CO2021008224A2 (es) | Inhibidores de kif18a | |
| ECSP22011692A (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 | |
| CU20180006A7 (es) | Compuestos de indazaol y azaindazol como inhibidores de irak-4 | |
| CL2018003511A1 (es) | Derivados de pirazolopirimidina como inhibidor de quinasa. | |
| CO2018008846A2 (es) | Derivados de carboxamida útiles como inhibidores de rsk | |
| MX2020000386A (es) | Inhibidores heterociclicos de la cinasa atr. | |
| MX2017000806A (es) | Derivados de 2-h-indazol como inhibidores de kinasas dependientes de ciclinas (cdk) y usos terapeuticos de los mismos. | |
| MX2024004162A (es) | Inhibidores de proteinas quinasas activadas por mitogeno p38 en sitio no atp/catalitico. | |
| MX2024015477A (es) | Compuestos de indazol | |
| CL2021000292A1 (es) | Benzimidazoles sustituidos como inhibidores de pad4. | |
| CO2022018806A2 (es) | Inhibidores de las cinasas receptoras del receptor del factor de crecimiento de fibroblastos | |
| MX383930B (es) | Compuestos de pirazol sustituidos como inhibidores de serina proteasa. | |
| MX2022003671A (es) | Inhibidores de proteina cinasa i de interaccion con receptores para el tratamiento de enfermedades. | |
| MX2019010554A (es) | Pirimidopirimidinonas utiles como inhibidores de la quinasa wee-1. | |
| CL2024001535A1 (es) | Quinolinas y azaquinolinas como inhibidores de cd38 | |
| MX2022004270A (es) | Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2. | |
| CL2021001363A1 (es) | Métodos de tratamiento de enfermedades con inhibidores de magl. | |
| MX2017009246A (es) | Farmaco de combinacion. | |
| CO2025003263A2 (es) | Inhibidores de kif18a y usos de estos | |
| CO2024009144A2 (es) | Inhibidores de cinasa met | |
| MX2022002443A (es) | Compuestos inhibidores de perk. | |
| EA202192575A1 (ru) | Соединения dbait в сочетании с ингибиторами киназ для лечения рака | |
| BR112019008622A2 (pt) | método para tratar uma condição |